EXPERIENCE OF SEVERE SYSTEM TYPE OF JUVENILE RHEUMATOID ARTHRITIS TREATMENT WITH CYCLOSPORINE IN COMBINATION WITH DIFFERENT METHOTREXATE REGIMEN
Abstract
Key words: children, juvenile rheumatoid arthritis, cyclosporine, methotrexate.
(Voprosy sovremennoi pediatrii — Current Pediatrics. 2009;8(4):142-150)
About the Authors
T.M. BzarovaRussian Federation
E.I. Alexeeva
Russian Federation
S.I. Valieva
Russian Federation
A.O. Lisitsin
Russian Federation
References
1. Szer I. S., Kimura Y., Malleson P. N. et al. Arthritis in children and Adolescents. Juvenile Idiopathic Arthritis. Oxford: University Press. 2006. 456 p.
2. Cassidy J., Petty R. eds. Texbook of paediatric rheumatology, 5th Ed. Elsevier Saunders. 2005.
3. Бзарова Т.М., Алексеева Е. И., Петеркова В. А. Роль факторов болезни и факторов противоревматической терапии в развитии низкорослости у детей, страдающих ювенильным ревматоидным артритом. Вопросы современной педиатрии. 2006; 5 (5): 13–18.
4. Алексеева Е. И., Литвицкий П. Ф. Ревматоидный артрит. Этиология, патогенез. Клиника. Алгоритмы диагностики и лечения. М.: Веди. 2007. 359 с.
5. Алексеева Е. И., Шахбазян И. Е. Принципы патогенетической терапии тяжелых системных вариантов ювенильного ревматоидного артрита. Серия «Аутоиммунные болезни». № 5. М. 2002. 127 с.
6. Reiff A., Shaham B., Wood B. P. et al. High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin. Exp. Rheumatol. 1995; 13 (1): 113–118.
7. Hashkes P. J., Laxer R. M. Medical treatment of juvenile idiopathic arthritis. JAMA. 2005; 294 (13): 1671–1684.
8. Tambic-Bukovac L., Malcic I., Prohic A. Personal experience with methotrexate in the treatment of idiopathic juvenile arthritis. Rheumatism. 2002; 49 (1): 20–24.
9. Ravelli A., Viola S., Migliavacca D. et al. The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis. J. Pediatr. 1999; 135 (3): 316–320.
10. Woo P., Southwood T. R., Prieur A. M. et al. Randomized, placebocontrolled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthr. Rheum. 2000; 43 (8): 1849–1857.
11. Chikanza I. C. Juvenile rheumatoid arthritis: therapeutic perspectives. Paediatr. Drugs. 2002; 4 (5): 335–348.
12. Ferraccioli G. F., Gremese E., Tomietto P. et al. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Rheumatol. 2002; 41: 892–898.
13. Tugwell P., Pincus T., Yocum D. et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N. Eng. J. Rheumatol. 1995; 333 (3): 137–142.
14. Garrood T., Scott D. L. Combination therapy with disease modifying anti–rheumatic drugs in rheumatoid arthritis. Bio. Drugs. 2001; 15 (8): 543–561.
15. Алексеева Е. И., Алексеева А.М., Валиева С. И. Влияние инфликсимаба на клинические и лабораторные показатели активности при различных вариантах юношеского артрита. Вопросы современной педиатрии. 2008; 7 (2): 42–54.
16. Guthrie B., Rouster–Stevens K. A., Reynolds S. L. Review of medications used in juvenile rheumatoid arthritis. Pediatr. Emerg. Care. 2007; 23 (1): 38–46.
17. Wallace C. A. Current management of juvenile idiopathic arthritis. Best Pract. Res. Clin. Rheumatol. 2006; 20 (2): 279–300.
18. Papadopoulos N. G., Alamanos Y., Papadopoulos I. A. et al. Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study. J. Rheumatol. 2002; 29 (2): 261–266.
19. Aletaha D., Smolen J.S. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford). 2002; 41 (12): 1367–1374.
20. Алексеева Е.И., Шахбазян И.Е. Сандиммун–Неорал — новое качество жизни для больных с тяжелым системным ювенильным ревматоидным артритом. Терапевтический архив. 1999; 71 (5): 26–29.
21. Gerloni V., Cimaz R., Gattinara M. et al. Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10 year prospective study. Rheumatol. (Oxford). 2001; 40 (8): 907–913.
22. Drosos A. A., Voulgari P. V., Katsaraki A. et al. Influence of cyclosporin A on radiological progression in early rheumatoid arthritis patients: a 42 month prospective study. Rheumatol. Int. 2000; 19 (3): 113–118.
23. Sarzi–Puttini P., D'Ingianna E., Fumagalli M. et al. An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis. Rheumatol. Int. 2005; 25 (1): 15–22.
24. Darmawan J., Rasker J. J., Nuralim H. Ten year radiographic outcome in patients with rheumatoid factor positive rheumatoid arthritis treated with aggressive immunosuppressive combination therapy. J. Rheumatol. Suppl. 2004; 69: 66–69.
25. Marchesoni A., Battafarano N., Arreghini M. et al. Radiographic progression in early rheumatoid arthritis: a 12 month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatol (Oxford). 2003; 42 (12): 1545–1549.
26. Gerards A.H., Landewe R.B.M., Prins A.P.A. et al. Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. Ann. Rheum. Dis. 2003; 62: 291–296.
27. Fox R.I., Morgan S.L., Smith H.T. et al. Combined oral cyclosporine and methotrexate therapy in patients with rheumatoid arthritis elevates methotrexate levels and reduces 7–hydroxymetho trexate levels when compared with methotrexate alone. Rheumatol. 2003; 42: 989–994.
28. Giacomelli R., Cipriani P., Matucci Cerinic M. et al. Combination therapy with cyclosporine and methotrexate in patients with early rheumatoid arthritis soon inhibits TNF–alpha production without decreasing TNF–alpha mRNA levels. An in vivo and in vitro study. Clin. Exp. Rheumatol. 2002; 20 (3): 365–372.
29. Giacomelli R., Cipriani P., Matucci Cerinic M. et al. Combination therapy with cyclosporine and methotrexate in patients with early rheumatoid arthritis soon inhibits TNF–alpha production without decreasing TNF alpha mRNA levels. An in vivo and in vitro study. Clin. Exp. Rheumatol. 2002; 20 (3): 365–372.
30. Алексеева Е. И., Шахбазян И. Е., Валиева С. И. Опыт пятнадцатилетнего применения циклоспорина в детской ревматологии. Вопросы современной педиатрии. 2008; 7 (6): 104–117.
Review
For citations:
Bzarova T., Alexeeva E., Valieva S., Lisitsin A. EXPERIENCE OF SEVERE SYSTEM TYPE OF JUVENILE RHEUMATOID ARTHRITIS TREATMENT WITH CYCLOSPORINE IN COMBINATION WITH DIFFERENT METHOTREXATE REGIMEN. Current Pediatrics. 2009;8(4):142-150.
Email this article 
